Diabetes lecture anniversary celebration in Oberndorf

This Saturday loads the diabetic group Oberndorf at one of its tenth anniversary at the Jubilee Celebration "Yesterday-Today-Tomorrow" in the local parish hall. During this event the general Erich Auer gives a talk on "The development of diabetes from the perspective of the family doctor", then the Diaetologinnen Monika Mayr, Susanne Kreische introduce the diabetes clinic at the hospital Oberndorf. Then the speakers at the visitors answer your questions about diabetes is available. Also for the physical well-being is taken care of. Admission is free for all. Voluntary donations are welcome and will be used by Oberndorfer Support for projects for children with diabetes.

Diabetes drug with side effects: Less Cancer

Drugs often have side effects, sometimes even serious side effects, and some even have been suspected to cause cancer. But in this case, a diabetes drug it is a different way. AOK-media mp Dusseldorf - Drugs often have side effects, sometimes even serious side effects, and some even have been suspected to cause cancer. But in this case, a diabetes drug it is a different way. AOK-media By Detlef Wilkens 2. Oct 2009, 16:23 Drugs often have side effects, sometimes even serious side effects, and some even have been suspected to cause cancer. But in this case it is a different kind: the diabetes drug metformin reduced the likelihood of developing cancer. This report by researchers at the University of Dundee in Scotland in the journal 'Diabetes Care'. They assessed data from diabetic patients treated with metformin and compared them with a control group of diabetic patients taking metformin no. Because of the mode of action of the drug, the krebsunterdrückende effect is suspected for some time. The drug is contraindicated in patients with type 2 diabetes, the most frequently used drug. The Scottish researchers collected data from 4 085 diabetic patients who were treated from 1994 to 2003 for the first time with it. 297 patients developed cancer during the investigation period. These data were compared with 4 085 diabetics who were not treated with metformin. Of these, 474 persons became ill with cancer. Taking into account various factors was based on these data, a calculated probability of disease decreased by 37 percent. The researchers now hope to be able to better protect people with high risk of cancer by preventive administration of metformin. It could also be stopped, at least in patients with cancer tumor growth. But up to the use of metformin to prevent cancer, it is still a long way: Clinical studies in humans to confirm the action and, above all, to clarify the spectrum of adverse events, which is in non-diabetics not enough research. This could for example, increased intake of sugar from the blood in non-diabetic patients, lead to hypoglycemia, especially metformin also suppresses the formation of sugar in the liver. What are the effects of simulated by metformin, but not present sugar shortage in the cell would have non-diabetics, is also still unclear

Diabetes Type I: At 21 for the first time an ice lolly

The intention of this study was to show the change in dietary recommendations and thus also the dietary habits of Type I diabetes. Great influence on these changes was the introduction of intensive insulin therapy and glucose tolerance in diabetic diet. To test the validity of the hypothesis was conducted in the present study, a survey by twelve in-depth interviews with diabetes aged 17 to 36 years. The diabetes duration should be at least seven years, so that the interviewees were able to make a statement about the changes in the selection of products suitable for diabetics. 1. With the exception of four subjects participated in the form of glucose, all more or less complex carbohydrates to himself. Finally, they describe the difference of behavior with the conventional insulin therapy, which was invariably described as a major limitation. Also exclude those respondents, the glucose from their diet, can confirm that the intensified insulin therapy to bind to Clock and diet plan has largely lifted.

Step toward diabetes prevention

Researchers have identified mechanisms that may contribute to the fight against diabetes mellitus type 2. They conduct research on beta-cells from the pancreatic islets of the pancreas that are responsible for the production and secretion of insulin. Diabetes mellitus occurs when the beta cells fail to pancreatic islets. This oxidative stress, for which the beta cells are particularly sensitive plays an important role. As a result of excessive nutrient intake leads to an excess of insulin secretion and insulin resistance in the main target tissues of insulin, ie, liver, muscle and fat tissue. Insulin resistance and other nutrient intakes, forcing the beta cells that process more and more nutrients, and secrete more insulin - through the nutrient metabolism of oxidative stress arises, for example by endogenous hydrogen peroxide and nitric oxide. As a result of this overload either the insulin secretion of beta-cells diminishes or it comes to the death by programmed cell death, or apoptosis. When insulin resistance, not by the activity of beta-cells can be compensated, there is the disease of diabetes mellitus type 2. Beta-cells regulate antioxidant enzymes Researchers led by Professor Gisela Drews have developed in the in vitro experiments on beta-cells from mice, a method to protect these cells from oxidative stress and thus reduce their injury. The pharmacists have discovered how the beta cells through certain agents that can upregulate attack on certain ion channels, anti-oxidative enzymes and thus counteract the congestion. The so-treated cells are largely protected as compared to a control against the influence of oxidants such as hydrogen peroxide and nitric oxide. The protection consists of both in terms of insulin secretion as well as apoptosis. The identified active substances are used today to treat diabetes mellitus type 2. The findings of the Tübingen scientists now suggests that the active ingredients can also be used for the prevention of the disease. Before the results can lead the work on mouse cells to a therapeutic application, however, still require years of research. About eight percent of the population are currently suffering from diabetes mellitus type 2, can bring complications like heart attacks, strokes or kidney failure with it. In addition to genetic predisposition for the development of this form, a überkalorische diabetes diet, usually associated with physical inactivity is responsible. At increasingly younger ages of overweight and obesity occur, so that the average age is 55 years, declined in the last decade to now under 30 years.

EU Commission leaves-2-diabetes means "Onglyza" AstraZeneca's

AstraZeneca Plc and Bristol-Myers Squibb Co. have received for their diabetes-2-Medium "Onglyza" marketing approval from the European Commission. "The decision marks the European Commission an important milestone in the cooperation of both companies," said Bristol-Europe president Beatrice Cazala on Monday. The Diabetes 2 funding is the first jointly-developed drug that is marketed by both companies in Europe to market. In Europe suffer according to the company about 53 million people with diabetes. The U.S. Food and Drug Administration had already given its approval for Onglyza in July.

Diabetes in French Polynesia: a collective issue

The House of the diabetic, whose activities started in October 2003, several missions information and therapeutic care that are financed mainly by EPAP, a public administration for prevention. One of his goals is to help people with diabetes live better every day with their disease and to delay the complications it entails. But another facet of its activities, not least, is to establish a prevention program to the general public.

If Type 1 diabetes accounts for only 5% of the Polynesian population is mainly diabetes type 2, which concerned health authorities for several years, hence the creation of this structure paramedical there nearly six years .

20% of the population concerned The Polynesian genetic predisposition for this type of pathology, but also favorable environmental conditions (70% of the population is over-weight, a sedentary lifestyle due to increased urbanization ...) so require increased action and overall prevention. The health consequences are indeed obvious to the patient: risks of heart problems, blindness, amputation, required daily dialysis ...

The consequences for society are not less (sickness absence ...), and the financial impact of the management of these patients by the CPS (Caisse de Prevoyance Sociale) is far from negligible with present approximately 8,000 patients in care.These figures are however far from reflecting the reality with an estimated 20% of the population (approx. 50,000 people) people who may be affected more or less seriously by this disease, whose symptoms did not find that very progressively screened out. The leaders of the House of diet - which works in partnership with the health structures of the country but also with two associations that manage screening campaigns - have reminded the Minister the main work of the MDD to try to stop this scourge. Information and prevention must be strengtheneThis sets up throughout the year various activities of information for a healthier lifestyle (diet, physical activity ...) from patients who are sent by physicians. 1175 people with diabetes have benefited from an educational care since the creation of the MDD. And a hundred professionals have been trained to facilitate an educational network as well as in the Tahiti islands. Moreover, there are actions in companies to inform employees. Different 'Dating Polynesian fight against diabetes, "which are organized in Tahiti since 2006 have proved such a success (nearly 2,500 visitors in 2006), and a new animation of this type is planned for November. The means are far from being commensurate with the stakes and the minister, who acknowledged the quality and the investment by the small team of ten people, has expressed "wanting to fight" for the human and more substantial financial are made to serve the collective cause.

Ride for Diabetes

Ride for Diabetes Research in 2009 will be held for the first time in Laval, October 2 at Centropolis. Ride for Diabetes Research 2009 of the Research Foundation Juvenile Diabetes (JDRF) will be held October 2, between 11h and 14h at Centropolis Laval.

This event, staged for the first time in Laval, will bring together participants from sectors of finance, insurance, legal and accounting sciences from Laval in a friendly competition to raise funds for research Diabetes. Indeed, the organizing committee of the event, chaired by Yannik Laurin, National Bank, hope to raise $ 100 000. Ride for Diabetes Research @ $ p> is a stationary bike challenge in which teams of five cyclists pedaling for 40 minutes (eight minutes by bicycle) and compete to earn more miles and collect the most money. "This event will be hosted by singer Daniel Lavoie and will take place rain or shine. This activity is known to be fierce competition, but friendship that already exists in a dozen cities in Quebec, "said the assistant communications JDRF Dominique Quirion. "It will be easy enough for each team to exceed the goal by raising $ 625," she added. The type 1 diabetes, the most severe form of diabetes is an autoimmune disease that can not be avoided and that affects more than 55 000 Quebecers. The type 1 diabetes can occur at any time in his life, for no particular reason. This number increases by 3% to 5% per year, the largest increase occurring in children five to nine years. Canada is in sixth place in the world in terms of incidence of type 1 diabetes. The causes of this disease are still unknown. Founded in 1974 in Montreal, JDRF is the largest charitable organization and the most active in research on type 1 diabetes in the world. JDRF's mission is to find a cure for juvenile diabetes and its complications through the support of research. "We want people to have a better quality of life," said Dominique Quirion.